Annabel Samimy
Stock Analyst at Stifel
(4.54)
# 283
Out of 5,182 analysts
57
Total ratings
51.85%
Success rate
39.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintains: Buy | $40 → $50 | $27.12 | +84.37% | 3 | Mar 5, 2026 | |
| EOLS Evolus | Maintains: Buy | $20 → $17 | $4.33 | +292.61% | 2 | Jan 13, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $13.33 | +35.03% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $49.95 | +10.11% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $9.04 | +397.79% | 3 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $27.16 | +91.46% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $32.81 | +52.39% | 2 | Dec 19, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $55 → $48 | $40.84 | +17.53% | 4 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $213.44 | +7.76% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $54.25 | +65.90% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $145 | $129.00 | +12.40% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.23 | +457.28% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $5.01 | +239.32% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.44 | +113.27% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $12.67 | +89.42% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $35.01 | +128.51% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $195.31 | +17.76% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.78 | +2,986.42% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $2.05 | +36,485.37% | 3 | Apr 16, 2020 |
Oculis Holding AG
Mar 5, 2026
Maintains: Buy
Price Target: $40 → $50
Current: $27.12
Upside: +84.37%
Evolus
Jan 13, 2026
Maintains: Buy
Price Target: $20 → $17
Current: $4.33
Upside: +292.61%
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $13.33
Upside: +35.03%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $49.95
Upside: +10.11%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $9.04
Upside: +397.79%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $27.16
Upside: +91.46%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $32.81
Upside: +52.39%
Apellis Pharmaceuticals
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $40.84
Upside: +17.53%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $213.44
Upside: +7.76%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $54.25
Upside: +65.90%
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $129.00
Upside: +12.40%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $3.23
Upside: +457.28%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $5.01
Upside: +239.32%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $8.44
Upside: +113.27%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $12.67
Upside: +89.42%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $35.01
Upside: +128.51%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $195.31
Upside: +17.76%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $0.78
Upside: +2,986.42%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $2.05
Upside: +36,485.37%